Fig. 2From: The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapyMultiplex immunohistochemistry panels displaying immune compositional changes in tumor microenvironment (n = 24)†. †As explorative setting, some cases with available tissues in HPD, non-HPD PD and PR/CR group. HPD hyperprogressive disease, Non-HPD PD non-HPD progressive disease, PR/CR partial response/complete response, TIL tumor infiltrating lymphocytes, NK natural killer cells, DC dendritic cellsBack to article page